Some individuals may experience temporary food sensitivities during treatment, though there is no established link between GLP-1 medications and permanent food intolerances
Some of these include: antibiotics antipsychotics antifungals medications for hypertension, heart disease, diabetes, and cancer antihistamines anti-arthritics bronchodilators antidepressants Medications can also have a long list of other side effects
Trials conducted between 2001 and 2007 demonstrated statistically significant reductions in body fat, although the larger Phase IIb OPTIONS trial did not replicate these findings at sufficient magnitude for regulatory approval, and formal development was discontinued in 2007
What are your areas of concern
AOD-9604 Jump to: Structure | Mechanism | Studies | Pharmacokinetics | Protocols | Limitations | Lead Researcher | References AOD-9604 Peptide Molecular Structure & Chemical Properties AOD-9604 represents a pioneering approach to peptide-based metabolic research, originally developed in the 1990s at Monash University in Australia as a potential anti-obesity therapeutic
The exception involves individuals with specific genetic variants in the MTHFR, MTR, or MTRR genes that impair B12 metabolism
,aspect=ignore)
